SciELO - Scientific Electronic Library Online

 
vol.11 número1Enfoques del aprendizaje en residentes de medicina de familia: un estudio mixtoResignificación del concepto «respuesta al placebo» a «respuesta al significado» en un grupo Balint con residentes de medicina familiar índice de autoresíndice de assuntospesquisa de artigos
Home Pagelista alfabética de periódicos  

Serviços Personalizados

Journal

Artigo

Indicadores

Links relacionados

  • Não possue artigos similaresSimilares em SciELO

Compartilhar


Revista mexicana de medicina familiar

versão On-line ISSN 2696-1296versão impressa ISSN 2007-9710

Resumo

FABELA-MENDOZA, Karla et al. Glycemic control in patients with type 2 diabetes mellitus according to treatment scheme. Rev. Mex. med. familiar [online]. 2024, vol.11, n.1, pp.9-16.  Epub 31-Maio-2024. ISSN 2696-1296.  https://doi.org/10.24875/rmf.23000114.

Background

The glicated hemoglobin A1c(HbA1c) measurement, whose value is below 7% indicates adequate glycemic control. The pharmacological regimens are based on five therapeutic classes.

Objective

Describe the treatment schemes used and make an indirectly compare them concerning glucose control, determined by HbA1c, in patients with type 2 diabetes mellitus (DM2).

Materials and methods

Descriptive, cross-sectional and retrospective study, with systematic sampling. Registration number R-2022-2402-046 was approved. Information based on records between January 2019 and December 2022. Patients with DM2, over 18 years of age, both sexes, with recent Hb1Ac, control parameter 7% or less and with the same pharmacological treatment for at least 3 months were included. Type 1 and gestational diabetes were excluded. Analysis with descriptive statistics.

Results

180 women (64.1%) and 101 men (35.9%) were included. 58 pharmacological regimens were used (58). HbA1c control percentages: monotherapy 50%, dual therapy 45%, triple therapy 48% and quadruple regimen 28% were used.

Conclusions

The percentage of glucose control varies about the type of pharmacological treatment and there is little use of new drugs. The large number of schemes used reveals not standardizing treatments, but rather considering the individuality of the patient.

Palavras-chave : Diabetes; Metformin; SGLT2i; GLP-1; Glycated hemoglobin.

        · resumo em Espanhol     · texto em Espanhol